
    
      In a recent systematic review, nearly 40% of HBsAg carriers and 5% of antiHBc-positive but
      HBsAg-negative patients developed HBVr during TNF inhibitor therapy.

      Considering the lifelong use of multiple antirheumatic drugs, we need more specific
      guidelines for the management of rheumatic disease patients who are scheduled to receive
      biological and/or non-biological DMARDs.
    
  